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Volume 6Available online 18 June 2021Background: The role of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) induction coupled with
standard concurrent chemoradiotherapy (CRT) is unclear in unresectable, stage III, EGFR-mutant non-small-cell lung
cancer (NSCLC). Therefore, a phase II trial was conducted to evaluate the efficacy and safety of gefitinib induction
followed by CRT in this disease setting.
Patients and methods: Patients with unresectable, EGFR-mutant, stage III NSCLC were administered gefitinib
monotherapy (250 mg/day) for 8 weeks. Subsequently, patients without disease progression during induction
therapy were administered cisplatin and docetaxel (40 mg/m2 each) on days 1, 8, 29, and 36 with concurrent
radiotherapy at a total dose of 60 Gy. The primary endpoint was the 2-year overall survival (OS) rate, which was
hypothesized to reach 85%, with a threshold of the lower limit of 60%.
Results: Twenty patients (median age: 66 years; male/female: 9/11; histology: 20 adenocarcinoma; stage IIIA/IIIB: 9/11;
and exon 19/21: 10/10) were enrolled. The 2-year OS rate was 90% (90% confidence interval: 71.4% to 96.8%),
indicating that this trial met the primary objective. The overall response rate and 1- and 2-year progression-free
survival rates were 85.0%, 58.1%, and 36.9%, respectively. Grade 3 adverse events (>10%) included hepatic
toxicity during the induction phase and neutropenia and febrile neutropenia in the CRT phase. Radiation
pneumonitis grade 3 or treatment-related death did not occur.
Conclusions: This is the first prospective study to demonstrate the favorable efficacy and safety of EGFR-TKI induction
followed by standard CRT in EGFR-mutant, stage III NSCLC. Further confirmatory studies are needed.
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Locally advanced non-small-cell lung cancer (NSCLC) can
potentially be cured with platinum-based chemo-
radiotherapy (CRT).1-5 However, most patients show
recurrence, with 5-year progression-free survival (PFS) andondence to: Dr Katsuyuki Hotta, Center for Clinical Innovative Med-
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- Issue 4 - 2021overall survival (OS) rates of 15% and 20%, respectively.1-5
Thus, further development of novel treatment modalities
is required to improve treatment outcomes.
The discovery of epidermal growth factor receptor (EGFR)
mutations has generated novel targeted therapeutic ap-
proaches for advanced disease. Gefitinib, an EGFR-tyrosine
kinase inhibitor (EGFR-TKI), yielded a greater PFS advan-
tage over platinum-based chemotherapy.6 Osimertinib, a
third-generation EGFR-TKI, has also shown a significant
survival advantage over gefitinib or erlotinib [OS hazard
ratio: 0.799 (0.641-0.997)].7,8 Currently, EGFR-TKI is a key
agent in EGFR-mutated advanced disease settings.6-8 How-
ever, the role of EGFR-TKI remains unclear in unresectable,
stage III, EGFR-mutant NSCLC, although even in this settinghttps://doi.org/10.1016/j.esmoop.2021.100191 1
ESMO Open K. Hotta et al.EGFR mutations can be detected in 17%-30% of patients,
particularly those with non-squamous tumors.9-12
Additionally, it is theoretically suggested that as the tu-
mor volume increases, the doubling time may be prolonged
and then the percentage of tumor cells in the proliferative
phase may decrease.13 In addition, the rate of tumor
shrinkage following treatment may depend on the tumor
growth rate.13 Therefore, EGFR-mutant tumors might be
made more sensitive to subsequent CRT by reducing the
tumor volume by initial exposure to EGFR-TKI, a highly
sensitive molecularly targeted therapy.
We carried out a phase II trial (clinical trial registration
number: UMIN 000005086, https://upload.umin.ac.jp/cgi-
open-bin/ctr/ctr.cgi?function¼brows&action¼brows&recpt
no¼R000006047&type¼summary&language¼E) to eval-
uate the efficacy and safety of gefitinib induction followed
by standard CRT in patients with unresectable, stage III,
EGFR-mutant NSCLC.PATIENTS AND METHODS
Patient eligibility
The eligibility criteria were previously documented in
detail,14,15 including: age 74 years; Eastern Cooperative
Oncology Group performance status of 0-1; pathologically
proven, unresectable, stage IIIA/IIIB diseases with mutated
EGFR in exon 19 or 21 but not in exon 20 T790M; and
presence of any measurable lesion. The seventh lung cancer
TNM (tumorenodeemetastasis) classification and staging
system was applied for staging. Pathological confirmation of
nodal involvement was recommended.
Each participant provided written informed consent
before the study. This study was conducted in compliance
with the principles of the Declaration of Helsinki, with
approval from the institutional review boards of all
participating institutes [Okayama University Hospital Ethics
Committee (approval no. rin1045)].Treatment
Interventional treatment consisted of induction and CRT
phases (Supplementary Figure S1, available at https://doi.
org/10.1016/j.esmoop.2021.100191). In the induction
phase, gefitinib was administered at a dose of 250 mg/day
for 8 weeks. Assuming the potential risk of developing
EGFR-TKI-related pneumonitis,16,17 sequential administra-
tion of gefitinib was designed before CRT to prevent
overlapping radiation pneumonitis. We used 8-week
administration of gefitinib because this time period is
nearly equal to that of neoadjuvant chemotherapy, which is
typically composed of two cycles.18
For the CRT phase, CRT treatment was started 2 weeks
after completion of the induction phase, under the condi-
tion that the disease had not progressed. The regimen
consisted of docetaxel 40 mg/m2 and cisplatin 40 mg/m2 on
days 1, 8, 29, and 36, and no additional cycles were planned
as consolidative therapy.2 https://doi.org/10.1016/j.esmoop.2021.100191Three-dimensional conformal thoracic irradiation was
initiated concurrently from day 1 of chemotherapy using a
linear accelerator (6-10 MV) in 2-Gy single daily fractions,
with a total dose of 60 Gy. The gross tumor volume rep-
resented the primary tumor and clinically positive lymph
nodes detected in radiological findings at the time of
diagnosis. The internal target volume was defined as the
area of gross tumor volume and ventilatory motion. The
clinical target volume and planning target volume margins
were set to 0.5 cm beyond the internal target volume and
at least 0.5 cm beyond the clinical target volume, respec-
tively. Regarding the response to gefitinib monotherapy, we
allowed the gross tumor volume to decrease if needed. The
volume of both lungs exposed to >20 Gy of the total vol-
ume of 35% or less was allowed.
We set the early feasibility step (step 1) with the first six
registered patients, to assess the feasibility of the inter-
ventional treatment throughout the induction and CRT
phases. We proceeded to step 2 when any of the following
events were observed in 2 of the 6 subjects: (i) grade 4
thrombocytopenia or anemia related to the interventional
treatment, (ii) grades 3-4 non-hematological toxicity related
to the interventional treatment, or (iii) pneumonitis. In step
2, no predefined interim analysis was set, and the same
intervention was used to assess efficacy.Endpoints and statistical analysis
The primary endpoint was set as the 2-year OS rate. Sec-
ondary endpoints included the objective response rate
(ORR), adverse events, treatment compliance, and PFS. The
treatment response was evaluated according to the stan-
dard RECIST version 1.1. Toxicity was assessed based on the
Common Terminology Criteria for Adverse Events version
4.0. Radiation pneumonitis was assessed during the delayed
period until 6 months after completing thoracic radiation as
well as during the acute period.
OS and PFS were calculated from the date of registration
until the date of death or the patient’s last visit and until
the first documented date of disease progression or death,
respectively. The survival curve was drawn by the Kaplane
Meier method. Statistical analyses were carried out with
SAS version 9.4 (SAS Institute, Cary, NC) and STATA version
11 (StataCorp, College Station, TX).
When assuming a 2-year OS rate as the primary endpoint,
historical data should be derived from the effect caused by
standard CRT in EGFR-mutant tumors; however, available
data were limited to EGFR-mutant tumors. Therefore, we
considered the lower limit of interest to be 60% yielded by
standard CRT in the EGFR-mutant-unselected population.1
The additional effect of single-agent gefitinib in the locally
advanced setting was expected to be 85% after the original
amendment,14 which was based on recent data for a 2-year
OS >80% with the addition of gefitinib to platinum, even in
the metastatic setting.19 Using a one-sided a ¼ 0.05 and
b ¼ 0.8, 21 patients were needed for this study by the
normal approximation to binomial distribution.Volume 6 - Issue 4 - 2021
Table 1. Patient characteristics (n [ 20)
K. Hotta et al. ESMO OpenDetailed methods and procedures followed have been
described in detail previously.14,15Clinical factors
Age, years




Performance status, n (%)
0 12 (60)
1 8 (40)




Type of EGFR mutations, n (%)
Exon 19 10 (50)
Exon 21 10 (50)
Disease stage, n (%)
IIIA 9 (45)
IIIB 11 (55)
Tumor histology, n (%)
Adenocarcinoma 20 (100)
EGFR, epidermal growth factor receptor.RESULTS
Patients and treatment delivery
Patient registration was initiated in April 2011; however, the
trial was terminated early with 20 of the planned 21 pa-
tients in January 2017 because of slow accrual. However, as
this planned number of patients was initially set to include
potential dropouts, the predefined statistical power was
successfully guaranteed with the registered 20 patients, all
of whom were assessed for the endpoints. The patient
demographics are listed in Table 1. Nine patients (45%)
were male, and 11 patients (55%) were diagnosed with
stage IIIB diseases. The N status was evaluated using posi-
tron emission tomographyecomputed tomography scan in
17 patients (85%), and 3 patients (15%) were staged using
invasive methods including endobronchial ultrasound-
guided transbronchial needle aspiration. Ten patients
(50%) had tumors with exon 19 deletions.
In the early feasibility step with the first six patients
[male/female: 3/3; median age: 64 years (range: 54-66
years)], two developed the predefined events (grade 3
aminotransferase elevation in both patients, and grade 3
febrile neutropenia in one patient). Thus, the step 1 feasi-
bility criteria were met (2 of 6), allowing the study to
proceed to step 2 and enrollment of the additional patient
cohort.
Overall, 17 (85%) patients completed gefitinib mono-
therapy. The administered days of therapy ranged from 30
to 56, with a median of 56 days. Three (15%) patients dis-
continued treatment because of disease progression, he-
patic injury, and the patient’s wish to undergo proton
therapy (n ¼ 1 each). Gefitinib treatment was interrupted in
5 of 20 patients because of hepatic toxicity (n ¼ 3), intes-
tinal infection (n ¼ 1), gingival infection (n ¼ 1), and
arthritis (n ¼ 1). Seventeen (85%) patients proceeded with
the CRT phase, 16 (94%) of whom completed CRT. However,
one (6%) patient, while awaiting recovery from myelosup-
pression that occurred after chemotherapy on day 29,
developed grade 1 radiation pneumonitis and was dis-
continued from treatment. Of the 17 patients administered
CRT, chemotherapy and thoracic irradiation were inter-
rupted in 13 (76.5%) and 6 (35.3%) patients, respectively,
mainly because of delayed myelosuppression. Finally, 16
(80%) of the registered 20 patients completed the entire
induction therapy and CRT.Survival and response
All patients were followed up to assess the primary
endpoint. The median follow-up time in the survival analysis
was 47.5 months (range: 9.5-96.8). The 2-year OS rate was
90.0% [90% and 95% confidence intervals (CIs): 71.4% to
96.8% and 65.6% to 97.4%, respectively], which met the
predefined criteria (Figure 1A). For PFS, the 1- and 2-yearVolume 6 - Issue 4 - 2021rates were 58.1% (95% CI: 33.4% to 76.4%) and 36.9%
(95% CI: 16.6% to 57.6%), respectively (Figure 1B).
The ORR was 75.0% (15 of 20 patients; 95% CI: 56.0% to
94.0%) in the induction phase (Table 2). Throughout the
treatment phase, 1 (5.0%) and 16 (80.0%) patients achieved
complete and partial responses, respectively, with an ORR
of 85.0% (95% CI: 69.4% to 100%).
No large differences in the overall response or survival
were evident according to the types of EGFR mutations and
other clinical factors (Supplementary Table S1, available at
https://doi.org/10.1016/j.esmoop.2021.100191).
Toxicity
The toxicity profiles for the study treatment are listed in
Table 3. Hepatic dysfunction was most common during the
induction phase, with grade 3 aspartate aminotransferase
and alanine aminotransferase elevations of 25% and 45%,
respectively. One patient developed grade 3 transient
gingival infection that did not require invasive intervention.
Myelosuppression was less common, and no patients
developed pneumonitis. In contrast, hematological toxicity
was prominent during the CRT phase, with grade 3
leukopenia and neutropenia at 77% and 65%, respectively.
Febrile neutropenia occurred in 12% of patients, without
fatal events. Aspartate aminotransferase and alanine
aminotransferase elevations were less frequently observed.
For radiation-related toxicity, 4 (24%) and 12 (71%) patients
developed grade 2 dermatitis and esophagitis, respec-
tively, without any grade 3 cases.
Radiation pneumonitis, the most clinically important
toxicity, occurred in 12 (71%; grade 1) and 2 (12%; grade 2)
patients; these events improved within 6 months after the
completion of thoracic irradiation. No clinical factor influ-
enced substantially pneumonitis-free survival rates, calcu-
lated from the day of CRT initiation (Supplementary
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Figure 1. KaplaneMeier survival curves of overall survival (A) and progression-free survival (B).
ESMO Open K. Hotta et al.Throughout the study treatment, no treatment-related
deaths were observed.Relapse sites and post-progression treatment
As shown in Table 4, as of the date of data cut-off, 15 (75%)
of the 20 patients experienced recurrences; 2 (10%) were
locoregional and 13 (65%) at distant sites. Thirteen were
administered post-progression EGFR-TKI monotherapy
(gefitinib in seven, afatinib in three, and erlotinib in three
patients).
DISCUSSION
This is the first study to demonstrate the clinical utility of
EGFR-TKI in an EGFR-mutant, locally advanced setting.
Single-agent gefitinib therapy followed by CRT showed4 https://doi.org/10.1016/j.esmoop.2021.100191favorable efficacy with a 2-year OS rate of 90.0% (90% CI:
71.4% to 96.8%). The ORR throughout the treatment pro-
tocol was 85.0% (17 of 20). The safety findings were
consistent with the known safety profiles of all agents
administered.
The 2-year OS, the primary endpoint, was favorable as
compared to existing survival data from a pivotal phase III
trial of an EGFR-mutation-unselected, stage III population
administered standard platinum-based CRT (2-year OS rate
of 45%-60%)1-3 and the recent, less robust retrospective
study results of w80% in EGFR-mutant, stage III disease
with standard CRT (Supplementary Table S3, available
at https://doi.org/10.1016/j.esmoop.2021.100191).9-12 We
also found a 2-year PFS rate of 36.9%, which appears
promising compared to EGFR-mutation-unselected popu-
lation data (20%-30%)1-3 and EGFR-mutant populationVolume 6 - Issue 4 - 2021






Locoregional node 2 (10)
Supraclavicular lymph node 1 (5)




Adrenal gland 1 (5)
Pleura 1 (5)
Liver 1 (5)





Complete response, n (%) 0 1 (5.0)
Partial response, n (%) 15 (75.0) 16 (80.0)
Stable disease, n (%) 4 (20.0) 2 (10.0)
Progressive disease, n (%) 1 (5.0) 1 (5.0)




a 95% confidence interval.
K. Hotta et al. ESMO Opendata (10%-25%)9-12 with standard CRT alone. Taken
together, these results support that our treatment proto-
col should be further evaluated.
However, most patients showed progression or recur-
rence (Figure 1B). The high 2-year OS may have arisen
mainly from retreatment with EGFR-TKI at recurrence
rather than as a preventive measure. Thus, it is unlikely that
gefitinib induction yielded an actual effect on the cure ratesTable 3. Toxicity
Any grade n (%) Grade ‡ 3 n (%)
Induction phase (n ¼ 20)
Leukopenia 1 (5) 0
Neutropenia 4 (20) 0
Anemia 8 (40) 0
Thrombocytopenia 5 (25) 0
Aspartate aminotransferase elevation 20 (100) 5 (25)
Alanine aminotransferase elevation 19 (95) 9 (45)
Creatinine elevation 1 (5) 0
Hyperbilirubinemia 1 (5) 0
Hyponatremia 3 (15) 0
Hypokalemia 3 (15) 0
Fatigue 4 (20) 0
Appetite loss 2 (10) 0
Diarrhea 4 (20) 0
Acneiform eruption 16 (80) 0
Oral mucositis 6 (30) 0
Pneumonitis 0 0
Gingival infection 1 (5) 1 (5)
Paronychia 2 (10) 0
CRT phase (n ¼ 17)
Leukopenia 17 (100) 13 (77)
Neutropenia 17 (100) 11 (65)
Anemia 14 (82) 0
Thrombocytopenia 14 (82) 0
Aspartate aminotransferase elevation 11 (65) 1 (6)
Alanine aminotransferase elevation 13 (77) 1 (6)
Creatinine elevation 2 (12) 0
Hyponatremia 16 (94) 1 (6)
Hypokalemia 5 (29) 1 (6)
Fatigue 9 (53) 1 (6)
Appetite loss 8 (47) 1 (6)
Diarrhea 6 (35) 0
Febrile neutropenia 2 (12) 2 (12)
Acneiform eruption 3 (18) 0
Oral mucositis 4 (24) 0
Depression 1 (6) 1 (6)
Syncope 1 (6) 1 (6)
Radiation dermatitis 4 (24) 0
Radiation esophagitis 12 (71) 0
Radiation pneumonitis 14 (82) 0
CRT, chemoradiotherapy.
Volume 6 - Issue 4 - 2021beyond prolongation from post-progression use of EGFR-
TKI. To achieve a higher cure rate, as a strategy for future
treatment development for EGFR-mutant, stage III disease,
it is essential to clarify how to incorporate EGFR-TKIs into
standard CRT. This includes evaluating the best time at
which to introduce EGFR-TKI while delivering standard CRT
and which generation of EGFR-TKIs should be used. The
LAURA study is ongoing, comparing consolidation EGFR-TKI
monotherapy with placebo in the post-CRT setting in EGFR-
mutant, stage III diseases (NCT03521154). In addition, we
are planning an exploratory phase II study to evaluate the
efficacy and safety of osimertinib induction and sequential
CRT followed by consolidative durvalumab therapy. This
design was derived based on the substantial survival
advantage of osimertinib over gefitinib8 and of durvalumab
consolidation over the placebo20 as described below. These
studies will provide insight into the tolerability and effec-
tiveness of adding the latest generation EGFR-TKI before or
after CRT.
Recently, the PACIFIC study revealed 2-year OS rates of
66.3% and 55.6% with and without durvalumab consolida-
tion therapy, respectively, in patients who achieved non-
progressive disease with standard platinum-based CRT.20
Patients in the placebo arm (n ¼ 236) were administered
standard CRT alone; their efficacy data should be consid-
ered as reliable historical control data based on our study.
However, these data have not been reported publicly,
although the 2-year PFS rate can be estimated from the
KaplaneMeier curve as ~20%. Further, the PACIFIC data
were not produced in untreated, stage III population, but
limited to those who were successfully administered stan-
dard CRT without progression at the time of completion.
Because of this difference in the targeted populations of the
PACIFIC study, we were unable to accurately compare the
efficacy data in this study. In addition, we should note that
the survival advantage of durvalumab consolidation in
EGFR-mutated NSCLC has not been fully understood
because of the limited registered number of this subpop-
ulation,20 and that its use has been recently questioned in
several retrospective studies.21-23
As for adverse events, gefitinib induction induced hepatic
insufficiency with a grade 3 alanine aminotransferasehttps://doi.org/10.1016/j.esmoop.2021.100191 5
ESMO Open K. Hotta et al.elevation of 45%, although there were no treatment-related
deaths. A prior phase II trial of concurrent gefitinib therapy
with standard CRT also showed grade 3-4 alanine amino-
transferase elevations of 37.1% in 38 patients with EGFR-
mutation-unselected stage III diseases.24 However, few
adverse events in the induction phase occurred during the
subsequent CRT phase. Other adverse event profiles
throughout the induction and CRT phases were nearly
consistent with existing known safety profiles, including
pneumonitis.
There are several limitations to this study. Mainly, this
study was carried out to generate a hypothesis, and the
strength of our conclusions is limited by the small-scale,
exploratory nature of the study. Thus, careful interpreta-
tion is required. The target patients are quite rare; however,
considering their distinct clinical courses and outcomes of
those with EGFR wild-type tumors (Supplementary Table S3,
available at https://doi.org/10.1016/j.esmoop.2021.
100191), the development of treatment strategies specific
to this subpopulation is needed.
In conclusion, we provide the first evidence of the clinical
efficacy and safety of gefitinib induction in an EGFR-mutant,
unresectable, stage III population. Our results might raise a
critical point that needs to be evaluated in further studies
to improve the cure rate.25
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